Hengrui Pharma (600276.SH) announced that its HRS-4642 injection has recently been included in the list of breakthrough therapies by the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA). The proposed indication (or function): This product, in combination with gemcitabine and nab-paclitaxel, is intended for first-line treatment of advanced or metastatic pancreatic cancer carrying the KRAS G12D mutation.
According to Zhitong Finance, Hengrui Pharma (600276.SH) announced that its HRS-4642 injection has recently been included in the list of breakthrough therapies by the Center for Drug Evaluation of the National Medical Products Administration. The proposed indication (or primary function): This product, in combination with gemcitabine and nab-paclitaxel, is intended for first-line treatment of advanced or metastatic pancreatic cancer patients carrying the KRAS G12D mutation.
It is reported that pancreatic cancer is a common malignant tumor of the digestive tract. The latest global cancer statistics show that in 2022, there were 510,566 new cases of pancreatic cancer globally, ranking 12th among malignant tumors; the number of deaths was 467,005, ranking 6th among malignant tumors, accounting for approximately 5% of global cancer-related deaths. HRS-4642 injection is a KRAS G12D inhibitor independently developed by the company and is formulated as a liposome-based agent. This product specifically binds to KRAS G12D, inhibits the phosphorylation of MEK and ERK proteins, and exerts an anti-tumor effect. According to available information, no similar drugs have been approved for marketing domestically or internationally at this time.
